47 results
8-K
EX-1.1
ADAP
Adaptimmune Therapeutics Plc
2 Jun 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
4:49pm
time as agreed by the Company and the Representatives.
“General Disclosure Package” means any Issuer General Use Free Writing Prospectuses issued … Time, none of (A) the General Disclosure Package and (B) any individual Issuer Limited Use Free Writing Prospectus, when considered together
8-K
EX-1.1
ADAP
Adaptimmune Therapeutics Plc
22 Jan 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
5:30pm
or such other time as agreed by the Company and the Representative.
“General Disclosure Package” means any Issuer General Use Free Writing Prospectuses … . As of the Applicable Time, none of (A) the General Disclosure Package and (B) any individual Issuer Limited Use Free Writing Prospectus, when considered together
DRS
EX-10.2
ADAP
Adaptimmune Therapeutics Plc
5 Feb 15
Draft registration statement
12:00am
Package
means, with respect to the Initial Target Program, the Clinical Trial report, IND (or equivalent documents and documentation in jurisdictions … (including subcontractor data) agreed to be required as part of such data package and intended to allow GSK to determine whether it will exercise
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
8 Nov 22
Adaptimmune Reports Third-Quarter Financial Results and Business Update
7:42am
clinical package supports submission of the BLA for the proposed indication for the treatment of synovial sarcoma
FDA and Adaptimmune reached
CORRESP
606lyym8
18 Oct 18
Correspondence with SEC
12:00am
8-K/A
EX-99.1
9ffg0uimvaq7
27 Feb 19
CORRECTING and REPLACING — Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
5:16pm
8-K
EX-99.1
afqlslv
27 Feb 19
Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
7:43am
20-F
EX-4.14
p2rcb f6z
13 Oct 15
Annual report (foreign)
12:00am